{"schema_version":"secwatch.filing_event.v1","accession":"0001846253-24-000032","form_type":"8-K","ticker":"OABI","cik":"0001846253","company_name":"OmniAb, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.747841+00:00","generated_at":"2026-06-02T07:03:29.592291+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OmniAb Q1 2024 revenue drops to $3.8M; net loss widens to $19.0M","bullets":["Revenue $3.8M vs $16.9M YoY; net loss $19.0M ($0.19/share) vs $6.1M ($0.06/share) loss.","Cash and short-term investments $69.0M; expects 2024 cash use similar to 2023 excluding $35M milestone.","Signed three new license agreements; 80 active partners, 327 active programs, 31 in clinic.","Pipeline: batoclimab MG Phase 3 topline H2 2024; IMVT-1402 plans 4-5 registrational programs.","Guidance: 2024 operating expense flat vs 2023; cash use substantially lower in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001846253-24-000032","json":"https://secwatch.observer/filing/0001846253-24-000032.json","markdown":"https://secwatch.observer/filing/0001846253-24-000032.md","text":"https://secwatch.observer/filing/0001846253-24-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1846253/000184625324000032/0001846253-24-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1846253/000184625324000032/oabi-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:03:29.592291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc0753c2b59fca7568043318073f4c2b66010daa","claim":"OmniAb, Inc. reported the three months ended March 31, 2024 results: revenue $3.8 million, net income $19.0 million net loss, EPS $0.19 per share loss.","evidence_excerpt":"to continued progress by our partners and expansion of our technology as the year progresses.” First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $3.8 million, compared with $16.9 million for the same period in 2023, with the decrease primarily due to the recognition in the 2023 period of a $10 million milestone related to the first","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1846253/000184625324000032/0001846253-24-000032-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$3.8 million"},{"label":"Net income","value":"$19.0 million net loss"},{"label":"EPS","value":"$0.19 per share loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e6a765280b2430a289026f7abc382680ebc5863c","claim":"OmniAb, Inc. reported the first quarter of 2024 results: revenue $3.8 million, net income $19.0 million net loss, EPS $0.19 per share loss.","evidence_excerpt":"to continued progress by our partners and expansion of our technology as the year progresses.” First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $3.8 million, compared with $16.9 million for the same period in 2023, with the decrease primarily due to the recognition in the 2023 period of a $10 million milestone related to the first","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1846253/000184625324000032/0001846253-24-000032-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Revenue","value":"$3.8 million"},{"label":"Net income","value":"$19.0 million net loss"},{"label":"EPS","value":"$0.19 per share loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}